Author

Borut Stabuc

CLINICAL AND BIOMARKER REMISSION IS MAINTAINED AFTER SWITCH FROM MONTHLY DOSED VEDOLIZUMAB TO THE NOVEL SUBCUTANEOUS FORMULATION IN INFLAMMATORY BOWEL DISEASE
CLINICAL AND BIOMARKER REMISSION IS MAINTAINED AFTER SWITCH FROM MONTHLY DOSED VEDOLIZUMAB TO THE NOVEL SUBCUTANEOUS FORMULATION IN INFLAMMATORY BOWEL DISEASE

Borut Stabuc  et al.

Item 1 - 1 / 1
1